Literature DB >> 9384586

Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1 A resolution.

P Cramer1, C J Larson, G L Verdine, C W Müller.   

Abstract

The crystal structure of human NF-kappaB p52 in its specific complex with the natural kappaB DNA binding site MHC H-2 has been solved at 2.1 A resolution. Whereas the overall structure resembles that of the NF-kappaB p50-DNA complex, pronounced differences are observed within the 'insert region'. This sequence segment differs in length between different Rel proteins. Compared with NF-kappaB p50, the compact alpha-helical insert region element is rotated away from the core of the N-terminal domain, opening up a mainly polar cleft. The insert region presents potential interaction surfaces to other proteins. The high resolution of the structure reveals many water molecules which mediate interactions in the protein-DNA interface. Additional complexity in Rel protein-DNA interaction comes from an extended interfacial water cavity that connects residues at the edge of the dimer interface to the central DNA bases. The observed water network might acount for differences in binding specificity between NF-kappaB p52 and NF-kappaB p50 homodimers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9384586      PMCID: PMC1170310          DOI: 10.1093/emboj/16.23.7078

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  46 in total

1.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

2.  Comparison of two different DNA-binding modes of the NF-kappa B p50 homodimer.

Authors:  C W Müller; F A Rey; S C Harrison
Journal:  Nat Struct Biol       Date:  1996-03

3.  Prediction of protein secondary structure at better than 70% accuracy.

Authors:  B Rost; C Sander
Journal:  J Mol Biol       Date:  1993-07-20       Impact factor: 5.469

Review 4.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 5.  NF-AT-AP-1 and Rel-bZIP: hybrid vigor and binding under the influence.

Authors:  G P Nolan
Journal:  Cell       Date:  1994-06-17       Impact factor: 41.582

6.  Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc.

Authors:  S A Wolfe; P Zhou; V Dötsch; L Chen; A You; S N Ho; G R Crabtree; G Wagner; G L Verdine
Journal:  Nature       Date:  1997-01-09       Impact factor: 49.962

7.  A critical arginine residue mediates cooperativity in the contact interface between transcription factors NFAT and AP-1.

Authors:  B R Peterson; L J Sun; G L Verdine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB-2/LYT-10.

Authors:  C C Chang; J Zhang; L Lombardi; A Neri; R Dalla-Favera
Journal:  Oncogene       Date:  1994-03       Impact factor: 9.867

9.  Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3).

Authors:  C S Duckett; N D Perkins; T F Kowalik; R M Schmid; E S Huang; A S Baldwin; G J Nabel
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

10.  Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction.

Authors:  R M Schmid; S Liptay; J C Betts; G J Nabel
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

View more
  36 in total

1.  Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family.

Authors:  F Michel; M Soler-Lopez; C Petosa; P Cramer; U Siebenlist; C W Müller
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

2.  Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha.

Authors:  G Xiao; M E Cvijic; A Fong; E W Harhaj; M T Uhlik; M Waterfield; S C Sun
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

3.  Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.

Authors:  Andrew S Liss; Henry R Bose
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.

Authors:  Béatrice Rayet; Yongjun Fan; Céline Gélinas
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

5.  Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer.

Authors:  De-Bin Huang; Don Vu; Laura A Cassiday; Jeff M Zimmerman; L James Maher; Gourisankar Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-28       Impact factor: 11.205

6.  Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit.

Authors:  Katie Schumm; Sonia Rocha; Jorge Caamano; Neil D Perkins
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

7.  Endoproteolytic processing of C-terminally truncated NF-kappaB2 precursors at kappaB-containing promoters.

Authors:  Guoliang Qing; Zhaoxia Qu; Gutian Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-15       Impact factor: 11.205

8.  NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites with two distinct modes.

Authors:  Amanda J Fusco; De-Bin Huang; Dustyn Miller; Vivien Ya-Fan Wang; Don Vu; Gourisankar Ghosh
Journal:  EMBO Rep       Date:  2008-12-19       Impact factor: 8.807

Review 9.  A structural guide to proteins of the NF-kappaB signaling module.

Authors:  Tom Huxford; Gourisankar Ghosh
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09       Impact factor: 10.005

Review 10.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.